<SEC-DOCUMENT>0001213900-20-009529.txt : 20200420
<SEC-HEADER>0001213900-20-009529.hdr.sgml : 20200420
<ACCEPTANCE-DATETIME>20200420060121
ACCESSION NUMBER:		0001213900-20-009529
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200420
FILED AS OF DATE:		20200420
DATE AS OF CHANGE:		20200420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		20801143

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea120830-6k_immuronlimited.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Month of April 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>IMMURON
LIMITED</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Level
3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&ldquo;Yes&rdquo; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (the &ldquo;Company&rdquo;) published one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities
Exchange on April 20, 2020 titled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
                                         Global Sales Up 60%&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Public Notice is attached as an exhibit to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 6-K (including the exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 91%; padding-right: 5.4pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><A HREF="ea120830ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron Global Sales Up 60%</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
    LIMITED</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;April
    20, 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Phillip Hains</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip
    Hains</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea120830ex99-1_immuron.htm
<DESCRIPTION>IMMURON GLOBAL SALES UP 60%
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Global Sales Up 60% </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Key
Highlights:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
                                         achieved 60% YoY growth in worldwide product sales in Q3 FY20.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YTD
                                         March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         Australia, Q3 FY20 gross sales grew by 35% YoY to $475K.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         the USA, Q3 FY20 gross sales increased by 50% YoY to AU $412K.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         Canada, Q3 FY20 sales reached $96K.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, April 20, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing
and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its
commercially available and over-the-counter gastrointestinal and digestive health immune supplement Travelan&reg; for the third
quarter of the fiscal year 2020 ending on March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
worldwide product sales grew by 60% YoY in the third quarter of FY20, reaching AU $983K* compared to AU $616K in Q3 FY19. YTD
March 31 worldwide sales reached AU $2.67M* marking a healthy 57% increase on the same time last year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Australia, Travelan&reg; sales increased to AU $475K* in Q3 FY20, representing a 35% increase over Q3 FY19 (AU $350K). Co-operative
marketing initiatives with Pharmacies, including a Chemist Warehouse TV advertisement in December 2019 contributed to this growth.
YTD March 31 sales in Australia reached AU $1.43M*, 35% higher than the same time last year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the US, Travelan&reg; sales continued their upward trajectory growing by 50% YoY to AU $412K* for Q3 2020. YTD March 31 US Sales
(AU $926K*) were 46% higher than the same time last year. This growth was attributable to increasing sales in both Passport Health
Travel Clinics and on the Amazon e-commerce channel. A consumer awareness campaign was launched in the USA in mid-February 2020
which generated valuable publicity for Travelan&reg; through a combination of earned media in digital news publications and through
Travel Influencer channels. The campaign was cut short due to the impact that the COVID-19 pandemic had on international travel
in late March.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Canada, Travelan&reg; sales reached $96K* in Q3 FY20 with Loblaws commencing distribution and Shoppers Drug Mart increasing scan
sales through co-operative marketing initiatives at store level. YTD March 31 Canadian sales were $313K* as brand awareness starts
to build in this market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right; background-color: white"><IMG SRC="ex99-1_003.jpg" ALT=""><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
mid to late March 2020, the COVID-19 pandemic resulted in international travel restrictions being enacted in all markets in which
Travelan&reg; is sold. It is anticipated these events will impact on Travelan&reg; sales in Q4 of FY20. The Company will look
to increase overall revenues to help mitigate the anticipated decrease in Travelan sales &ndash; due to decreased travel &ndash;
by promoting Travelan&reg; and Travelan&reg;'s sister product, Protectyn&reg;, for their gut health benefits. The market effort
will focus on the benefits that Travelan&reg; offers when it comes to maintaining digestive health. It is noteworthy that when
people stay at home to self-isolate, they sometimes make poor dietary choices such as eating takeaway food that has been transported
in uncontrolled temperatures or that has been poorly prepared, or which contains unhealthy ingredients. In addition, stress, changing
routines and weakened immunity can also lead to digestion issues. Travelan&reg; helps to maintain the delicate balance of the
gut microbiota by eliminating invading pathogens, whether you are travelling or self-isolating at home.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
CEO, Jerry Kanellos said &ldquo;This good news story has been overshadowed by the novel coronavirus that emerged in the central
Chinese city of Wuhan late last year. New cases are being reported daily around the globe and the world has been plunged into
turmoil. Since then, a pandemic has been announced by the World Health Organization and most governments have enacted states of
emergency and lockdown their borders to contain the virus and protect their citizens. As COVID-19 has spread, we have been monitoring
its global impact on clinical trials. <FONT STYLE="background-color: white">Major pharmaceutical and Biotechnology companies such
as Pfizer, Merck, GSK, Eli Lilly, Bristol Myers Squibb and others are delaying, or pause trials due to the pandemic. </FONT>While
this is a difficult time for so many, we have also decided to conserve our cash reserves and suspend all work associated with
the IND filing and postpone the planned phase III clinical program for IMM-124E to prevent Travelers&rsquo; Diarrhea which was
on track to submit an IND application to the FDA in June 2020 and to begin recruitment in July 2020 to coincide with the Northern
hemisphere summer holiday travel period. This decision will also impact the planned clinical development of our IMM-529 asset.
The company will continue the clinical development of a new oral therapeutic targeting travelers&rsquo; diarrhea caused by campylobacter
and enterotoxigenic <I>E.coli</I> pathogens with the Naval Medical Research Centre. The protective efficacy of the product will
be evaluated in two controlled human infection model clinical trials scheduled to commence in Q3 and Q4 next financial year. The
company will also continue to support the Uniformed Services University&rsquo;s Infectious Diseases Clinical Research Program
(IDCRP), the UK Ministry of Defense and the New York City Travel Clinic who are jointly conducting a randomized clinical trial
to evaluate the efficacy of Travelan and two other nutraceutical products for Travelers&rsquo; Diarrhea prevention. The randomized,
double-blind, placebo controlled multicenter clinical trial will evaluate the effectiveness of 3 commercially available products:
A prebiotic, a probiotic and Travelan&reg;, each vs. placebo, during deployment of military personnel to high-TD risk regions.
The first purchase order from the Uniformed Services University for Travelan&reg; was delivered this year. The continuing spread
of COVID-19 has everyone's undivided attention as we grapple with its effect on our daily lives. The pandemic has also caused
significant disruptions to global clinical development, and we send our best wishes and heart felt support to all those whose
lives and work have been affected by this outbreak&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Unaudited
gross revenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_003.jpg" ALT=""><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
CONTACT: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Jerry Kanellos, Ph.D.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ph: +61 (0)3 9824 5254</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com
</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan&reg;
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins
they produce</FONT>. Travelan&reg; is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors,
which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo;
diarrhea. In Australia, Travelan&reg; is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and
is indicated to reduce the risk of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial.
In Canada, Travelan&reg; is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo;
Diarrhea. In the U.S., Travelan&reg; is sold as a dietary supplement for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelers&rsquo; diarrhea</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelers&rsquo;
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal
cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli
</I>(ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The
more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the
causative agent of cholera) are often confused with travelers&rsquo; diarrhea as they may be contracted while travelling and initial
symptoms are often indistinguishable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally
delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel
and safe technology platform with one commercial asset generating revenue. In Australia, Travelan&reg; is a listed medicine on
the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licenced natural health
product (NPN 80046016) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as
a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product development programs and any other statements that are not historical
facts. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the
early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">3</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ $$# 2(  A$! Q$!_\0
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MKDC'+-(!^F0QKU.N+TXHGQ@UM GS2:3:N6]</(/\*[2@ HHHH , T@ %+10
M4444 %%%% '.PZ7<I\0KK5MG^B2Z7%;[\]9%ED./R8?G7148HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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M=_&?R,,%_!7S/&OBV/\ BI;4_P#3HO\ Z$U>B^"#GP7I?_7+_P!F->=_%O\
MY&6U_P"O1?\ T)J]$\#_ /(EZ7_UR/\ Z$:UK_[K#^NYG1_WJ?\ 78\C\1<?
M$6Z)_P"?T?\ H0KWRO!/'<,EAXZO7(QND69#Z@@'^>?RKV_2]1@U;3+>^MF#
M1S(&&.Q[@^X/%&,5Z=.2VM_D&#=JE2+WO_F7*\-^)O\ R.TW_7./_P!!%>Y$
M@#).!7S_ .,=037/&5U+:?O$9UBB*_QX 7(^I%++T_:-^0\P:]FEYGNFD\:-
M8_\ 7O'_ .@BO"O#\*S^/[-&&1]M#8^C9_I7O=I";>S@@/6.-4_(8KPGPM_R
M42S_ .OMOZT\(]*C\O\ ,G%K6FO/_(]\KR'0[$']H;6GN%^>.W,T6?=8QD?@
MQ%>O5Q'BG2Y=*\5Z=XSM(FD2W0V^HQHI+& Y_> #KMSDCT ]*Y:,K77='HHD
M\:6EYXAOK+PY:2B&.13<W4A[(#A>._.>/4"J]O\ "?0HT'G3WDK=SO51^6*U
M9KV&V\;6%P9%:VU*Q\F&53E2ZMN'/3D-QZ\5YI\9_%'B#3O$%OIMG=W%E8FW
M$BM Q0RL20<L.>, 8_QK>FZKY:<'96O_ )G,J,*DY.2NSUR"'2/"FBE0\5E8
MP LSR/@>Y)/4US_PUF2_T?5M3B0K:ZAJUQ<0 C&4) SCW(->#>'?#WB'QYJD
M<"2W,T2L/.NIW9DB'<DGOZ#J:^E5&G>#/"J1J?+L[&$*H)Y<_P#Q3']34U:?
M)[M[R9T-1A'R,KP-<%/[8TC.8].O72+_ &8R3@?F#^=>7ZTH?XC7*L,@ZA@C
M_@==]\+DFN+?5]5F&#>7/YD9)Q^+UP>K_P#)2Y_^PE_[/7715JU1>1Y59WHP
M?F>^4445Y)ZIX7\2P!XXN2!U2,G_ +X%>U:8Q?2;-FZF!"?^^17BWQ,_Y'>X
M_P!R/_T$5[3IG_(*L_\ K@G_ *"*[\5_!I_UT.#"_P :I_74\@^*L;GQ;&P1
ML&V3!Q[M7JWAU63PUI:NI5A:1 @C!'RBM(JK=0#]12USU*_/3C"VQT4Z')4E
M.^YX'K,4C_$6Y"HQ)U XP/\ ;KWRDVKG.T9]<4M.O7]JHJUK!1H>R<G>]SE_
MB&CR>"+\1J6/R$@#/&]<UQWPACD&H:DY1@GE*-V.,YKUDC(P:0*%&  /I1&O
MRTG2MN*5#FJJI?86O&/BO&[>*X2$8C[*G../O-7L](5#=0#]:FA6]E/FM<JO
M2]K#EO8R?"J-'X3TE74JPM8\@C!'RBO'/%D$L?C^\+1NH:Y##(Z@XYKWJD*J
MQR5!/N*NCB/9S<K;D5L/[2"C?86N?\<*S>"]3"J2?+' '^T*Z"CK6$)<LE+L
M;SCS1<>YY'\(HY!J^H,48*( "<<9W#_Z]>N4@4+T 'TI:TKU?:SY[6(H4O90
MY+W/'?BW&_\ PD=H^T[3:@ XX)W-7H?@E&C\&Z6KJ5/E9P1CN:WF16QN4''J
M*6JG7YJ4:=MB(4.6K*I?<XWQYX./B2T2YL]HU" 84$X$B_W<^OI]37E^G:YX
MA\'74EO'YD&3E[>=,J3ZX/\ ,5]!5%/:V]TNVX@BF7TD0,/UJZ.*Y(\DU=$5
ML+SRYX.S/"]5\>>(==MS9M(L4<GRM';)M+^V>3^%=)X \!W,=[%K&KPF)8CN
M@@<?,6[,P[ >G7/Z^F6^G6-HVZVL[>%O6.)5/Z"K-5/%KDY*<>5$PPCYN>I*
M["O!?"T4A^(=H51CBZ8GCMS7N-KJ%I?/,EK<1S- YCE"'.QO0U8"J#D* ?85
ME2K.DI1:W-:M%57&2>PM%5+;4[&\MY9[>ZBEBA)61U;(4@9.?PHL-3L=4B:2
MQNHKA$;:S1MG!]*PY6NAOS+N9OB#PU;ZSH;6$(6VDC;S;=T&!')Z\= <GIZU
MP[^*Q:[='\=:$MVT)^29XE<G_:P>#]0:]3DD2&)Y9&"(BEF9C@ #J36:)M%\
M164C9M+^VC)#$@.JG&?PXK>E4M&TU=?E\S&I!N7-"5I?F<H?B9X9TVR$6G6D
MVU1\D,4*QJ/\/P%<I+/X@^)6JI$L?DV$;<@9\N(>I/\ $V/\BNX.F> XK:._
M:'3A;R,521G)1B.HZXK4@\4>%[:)88-3L(HU^ZB,% _ 5O&<8:TH._=F$H2J
M:59JW9=32TK3+?1],@L+5<10K@9ZD]R?<GFO$=6@G/Q*G40N7.H;E7;R1OR*
M]G@\1:/=1320:E;R) N^5E?(1?4U7_X2WPX6W?VO99]?,%9T*E2G*3Y6VRZU
M.G4C%<R5C;HK/LM<TO41*;.^@G$2[I-C9VCU-5?^$O\ #O\ T&+/_OX*Y_9S
MVLSH]I#>Z/*?B7%(?&TQV-AHX]IQU^4"O9].!72[16!#"% 0>QVBBTO;+48A
M-:7$%R@_CB<,!^56:UJUG.$8-6L94J*A.4T[W"BBBN<Z HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#B? /_(0\3?]A)__ $)J[:N*\ _\
M?_B;_L)/_P"A-7:UOB/XC^7Y(QP_\-?/\V>?^"O^11U__KXG_P#0!69\/6;1
M[VP5F/V;68'*Y/2:-V&/^^?YBM/P5_R*.O\ _7Q/_P"@"J5K9RR_"K3=0MA_
MI6FRM=1'_=D;</ICG\*ZY6O.+ZM+\/\ ,Y(WM"2Z)O\ '_(Z;QQ<R?V1#I5N
MV+G5)EMEQV4GYC],<?C6/\/H$M=#U^W0DI%>2HI/H% JSI%W'XK\:?VI%\UE
MIMLJP^GFR#+?B!D'Z"H_ W_(,\2?]?\ -_Z"*RMRTG#T;^;_ ,C2_-54_5+Y
M+_,?\/;&TOO ]JEW:P7"K-(0)HPX!W>]5M1TG34^)VD6RZ?:+;O:.S1"%0K'
M#\D8P>@K1^&?_(E6_P#UUD_]"J+4_P#DJ^B_]>;_ ,I*')^VFK_S HKV,';^
M4O\ B;3;"Q\(ZNUI96UNS6S!C#$J9^N!6;X:'A3_ (1K3?M8T;[1]G3S/-$6
M_=CG.><UN>,/^10U7_KW:LKPQX7T.Z\+Z9//I=M)+);HSNR9+''4U$9+V-Y-
M[]/0N47[6T4MNOJ:\<>C#3+Y])2P ,3!VM GH< [:Y_X?:1IEWX.M9KG3K2:
M4O)EY(%9C\Y[D5TO]E6&E:5>I86D5NKQ,6$:XR=IK&^&W_(D6G^_)_Z&:7-^
MZDXM[K\F/E_>Q4DMG^:,SQ/IT'A&_P!/U_2(Q:H9U@NH8^$D0Y/3H.A_0UZ!
M7"^.KJ/5[K3/#EHRRW,UTLDP0Y\M #G/IU)_"NZI5;N$'+?7[NA5*RG)1VT^
M_J%%%%<YN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <M-
MX T2:ZGN"+I9)Y&D?9.0"Q.3_.K.F^#=+TN_BO;=KKS8\[=\Y8<@CD?C7045
MJZU1JSD9JC33ND9>G>'[#2[&ZL[99!#<NSR!GR26&#@]N!4VG:1::7I2:9;H
M3:J&&USNR&))S^9J]14.<GNRE"*V1FZ+H5CX?LVM=/C9(V<R-N;))( Z_@*-
M.T.RTJ&[BM5<+=2M++N;.688.*TJ*'.3O=[@H15K+8H:1I%IH>GK8V2LL*L6
M 9LG).323:+9SZW;ZNZO]KMXS&A#<8.>W_ C6A11SRNW?5AR1LE;1%>_LH=2
ML)K.X!,,RE'"G!Q7-K\.]#10JF\"C@ 7!XKK**<:DX*T784J<)N\E<Q=+\+Z
M?I"W"VQN"+A-C^9*6XYZ>G6LQ/AUH,:[4^V*OH+@@5UM%-5JB=TQ.C3:M8RM
B'\-Z3H08Z?:+&[\-(26<_B>?PK5HHJ)2<G=LN,5%62/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 S0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
M&944EB !W)K/N->TJUSYM_ ".H5MQ_(5482EI%7)E.,%>32-&BN8N?'>D0C]
MT)IS_LI@?K61<_$24Y%M8HOH9'+?H,5U0P&(G]FWKH<=3,L+#>=_34[ZD) &
M20 .YKRNY\::U<<"Y$0](T _7K^M9%QJ-Y=DFXN99<_WW)_G75#**C^.27XG
M'4SNDO@BW^'^9ZY<:YI=KD37T (Z@-N/Y"L>Y\=Z5#Q"LTY]0NT?KS^E>9EB
M>II,UUPRJBOB;?X'%4SFO+X4E^)VMS\0;ELBVLXH_0N2W^%8]SXLUFZSF\=%
M/:/"_P N:PLT%L#).![UUPPE"'PQ7Y_F<53&XBI\4W^7Y%B2ZGF??+,[MZLV
M315)KNW4X:>,'_>HKHLD<UVSWJBBH[B>.UMI;B9ML42%W/H ,FOBS[THZUKN
MG^'[(W6H3B-3PJCEG/H!7G-]\89?-(L-,C$8/69R21]!C%3PM8:A%/XU\5?/
M:%S'869^8%02!\O<D@\=.I-0Q?$.^U#=#9^&;633E./*<\$>F<;<^V#75"FE
MHHW8M+7EH6M)^+UO-,D6J6!A5C@RPMD#_@)_QKT>TN[>_M8[JUF2:"091U.0
M17AGB32M+U"R36]"B-LGF^1>63\?9Y#TQZ*<$>G\A=^&OB.;2=<&DW+,+6Z?
M9M;^"3H./?H?_K43I*4;Q5F-JVJ/;***X;XGZI?Z5HMG+I]W+;2/<;6:,X)&
MT\5C2INI-074BI-0BY/H=S17/6NM_P!G^ K?6+YWF:.S25R3\SL0/U)->>6!
M\:^.I9[RWU VEJC[0%E:*,'^Z-O)QQR:UIX9RNVTDM+LSG74;)*[?0]DHKQF
M3QAXL\(R76DZDRW$^P&&68[RF>C _P 0Z\'O^56%\/?$&YLAJO\ :DXF9?,6
M#[20Y'7[H&T'VK1X)K64TD]GW,_K2>D8MOKY'KU%<-\//&%SK\<^GZEAKVV4
M,) N/,3..1V(/\ZH^._%^I0:O%X>T,LET^T22( 7+-]U%]/4GWK-86I[7V77
M\+=S1XB'L_:=#T>BO(+S2?'OAJS.KMJKS+&-\R"=I=H_VE88(]<4R/7_ !=X
M\O?LNERBQABC!E\IRB@^I;KR>@%:?4[KF4TX]7V,_K5GRN+OV/8J*\<DU7Q9
MX U2W75+EKVREYVM(9%=1UVD\JPKM_'.JSV_@A]1TVYDA=S$T<L9P=K$?T-9
MRPLE**334MF7'$)QDVK-;HZRBN;\!WMSJ'@^SN;R=YYV+[I'.2<,13/B!?76
MG>$+FYLKB2"=7C DC.",L :S]D_:^RZWL:>T7L_:>5SIZ*X*RU;4)/A%-J3W
MDQOA#(PG)^<$.0#GZ5QVDZWXR\2PKI&G7DS.A:2:Y+[6P>@+=@/0<FMH8.4N
M9W22=F92Q48V5F[JY[=17D>M>)?$7A>QT_P=IC?VCXIO"SF8,9!"A8X/S=\9
MZ\ #-4+GP'JUE;IJ'B?XCW=G?2<JL4CL ?;Y@3CV %2L/KK+?;=W^1OS)1YI
M:>I[717FGA7Q'KNC:E::1XBO(]6L+]3_ &9J\ _UK 9,;C^]@''?C'/;T:WN
M(;J!9H)%DC;HP_SUK*=-P=F--/8EHKRSQ)XPUK6O$+:!X9+($<QM+'@,[#[Q
MW'[JCUJG>Z/X]\-6QU,:K+<)&-\JI.TNT>I5AR/I71'!NRYI)-[)G,\4KOEB
MVEU/7Z*YKP5XI'BC2&ED18[R!@DZ+T)QPP]C_0UTM<LX2A)QENCHA-3BI1V"
MBBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBJL^I6-KGS[RWBQ_?D II-Z)"<E'5LM45A7'C#0K?K?!S
MZ1H6_7&*R[CXBZ9&2(;:XE/J<*/YFMXX2O+:#.:>-P\-YK^O0[&BO.KCXDW+
M9^SV$2>A=BW\L5EW'CG7)QA;A(AZ1QC^N373'*\1+>R^9RSS?#1VN_E_F>LU
M7GOK2U!-Q=0Q8_OR ?SKQFXUS4[H_OKZX<>AD./RJD9">I/-=,,H?VI_<CEG
MG:^Q#[W_ )'K]QXNT2WZWH<^D:EOUQBLJX^(FGID06L\A]6(4'^=>:;J-U=,
M,KH1WN_Z\CDGG&)E\-E\O\SM;CXB7SY%O:01?[V6/]*RKCQAK=P3F]9!Z1@+
M^HYKG]U1M<PI]Z5!^-=,,)0AM!?UZG)/&XB?Q3?Y?D7Y[VYN3F>XDE/J[$_S
MJ L3U-46U*V7^,M]!4+:N@^Y$Q^IQ70K+1',[MW9J;J-U8CZM.?NHB_K4#WU
MR_69A].*+A8Z(L ,DX'O4+WMO']Z9/H#FN<9V?[S%OJ<TE*X^4W'U>W7[H=_
MH,57?67/^KA4>['-9=%%PLBV^IW;_P#+3;_NC%5GDDD.7=F^IS3:*!A1110!
M]15SOCN5X?!.J/&2&\M5R/0L ?T-=%6;XAL/[3\/WUF!DR1':,9Y'(_45\=!
MI239]U+8\=\42&]T[PC8PMBV-BG3IYA.US^:U47Q"5E^R:7IQEBB&$')) [X
M%4UU$V]K%IMZK"2PG,MK)_=R<LA_V21G/8Y]>.J\*ZU;>#Y;VX:RFNK&]"O#
M/;J&9,9^5@<>OZ5Z$7*$'RK44XPDUS;=#&M['4[;PWX@U+4H)+>"[2.-%E4I
MYDIE5@0#Z -S[UE7.]&TB_0E9I%&XCJ61L9_+%;WB#7-5\=WT426[6NG0ME5
M;IG^\3W..@'3]:;9Z>NL>*=/TRUYM[(!6; /.>?KVS]#3A=1<IBG)745Y_E8
M]SKSOXO?\@"P_P"OK_V0UZ)7G?Q?(&@6&3C_ $K_ -D-<N#_ (\3/%?P9#]<
M_P"2,P_]>EO_ #6M#X8*!X)@([S2D_\ ?1K.UPC_ (4Q"<\?9+?^:UH_# @^
M"+;!S^]E_P#0C6U3_=Y?XO\ ,RA_'C_A.5^*BJ?%>D9 ^:( ^X\RO6Z\D^*A
M \5Z-D@?NQ_Z,KUNHQ'\&EZ/\RJ/\6IZK\CR3X>@#XBZN ,#;/\ ^C127(S\
M<(_^NZ_^BJ/AZ1_PL;6!D9VS_P#HT4EP1_PO%!D9\]?_ $579+^-/_!^ARQ_
MA1_Q?J>G:X V@:D",@VLO_H)K@O@XH_L_56QR98QG_@)_P :[W6_^0#J/_7K
M+_Z":X+X.$'3-4P0?WT?_H-<=+_=:GJCJJ?[Q#T9+\8 /[%TX]Q<$?\ CAI_
MBK_DD-G_ -<;;_V6F?& @:)IV3C_ $D_^@&MQ]'_ +>^&MMIZ,!))8Q&-CT#
MA01^HK6,E&C2D]E)F<HN56HEV0GPW_Y$:Q^LG_H9IGQ,_P"1'NO^ND7_ *&*
MXOPEXUD\'K-HFM64XCCD+*%'SQ$]1@]1GD$4WQ7XPF\:O;Z+HME,8FD#$,!O
MD8=.!]U1UR:OZM4^L\]O=O>_2VY/MX>PY.MK6-S3_P#DB$__ %[R_P#H9JS\
M)+=$\-W=P!\\MT58^RJ,?S-7=6TH:'\*KK3MP9H+,AV'0L3DG\R:@^$Y!\(2
M8.?]+D_DM1.7-0J26SD7"-JT$^D2MH5HD7Q?\7W]VN9H[6V,!;DB(KR1^*8_
M"J$G@_\ M^ ^)/$FM"S6Y D125"Q1G[BEF.!QCBN[U#11/JL&K6K+'>Q1F!]
MWW9X2<E&^AY!['V)KS+Q;IL>H:1%X0UV_;3)+*;S;"]DC+PSQ8("OCH0#C/M
M4T)R;O!V>GF[+L5B84Y2BJWP_A?S_0U;_4/#5M8Z'X3T._CU"_.HP2Q>3()#
M'MD#O(S+P/E#?G736=U]B\?:EIL9_<W-HMYL'19 =K'\1@GZ5Q'AG3_!?PWM
MY-074TU?5W3:KQ ?*#_"H&0H/<DY_E73>";34-1OM0\4ZI&8I+U?+MXR/NQC
M^G QZX)[TYPM&4I7MY]6VB95(.<*5+IVZ*QSWPF4/X@U:5AEQ$,,>O+G/\A7
MK,BJ\3HP!5E((/<5Y/\ ",@ZWJ^"#^Z7_P!"->LM]T_2L\?_ !W\OR+P?\%?
M,\F^$9*ZSJT8X3REX^C'%>M5Y)\)"#KVKX(/[H?^AFO6Z,?_ !W\OR#!_P %
M?,****XSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **BEN8(!F6>.,?[;@50F
M\1Z+ 2'U.UR.RR!C^E5&$I?"FR)5(1^)I?,U**YN;QWX?A) NVD/HD3?U K.
MF^)>EH2(;6YD]R%4?S-;QP=>6T&82QV&CO-':T5YS/\ $]R2(-,0>[RD_P @
M*SI_B/K,A/EI;1#_ &4)/ZDUM'+,0]TE\SGEFV%CLV_D>KT5XO-XTU^<G=J#
MJ#V0!?Y"LV;5]0N2?.OKB3/]^0G^9K>.45'\4E^)SRSNFOABW]Q[G->VEO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
